基本信息
浏览量:3
职业迁徙
个人简介
I am involved in clinical research at the phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted therapy with kinase inhibitors, drugs that may target the CML stem cell and cells that are resistant to other therapies. The interest in targeted therapy extends into the phase II study of signal transduction inhibitors in the therapy of other diseases such as systemic mastocytosis and mast cell leukemia.
The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.
The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.
研究兴趣
论文共 59 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Drug Investigationno. 2 (2024): 91-108
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S527-S527
Samantha Tam,Rajat Kumar, Paty Lopez,Jonas Mattsson,Shabbir Alibhai,Eshetu G Atenafu,Lori J Bernstein,Eugene Chang, Susan Clarke,David Langelier,Jeffrey Lipton,Samantha Mayo,
PloS oneno. 5 (2023): e0285420-e0285420
引用0浏览0WOS引用
0
0
Leukemia & lymphomano. 12 (2023): 1-10
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn